2021
Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae
Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. The Lancet Global Health 2021, 9: e1679-e1687. PMID: 34798027, PMCID: PMC8609280, DOI: 10.1016/s2214-109x(21)00367-3.Peer-Reviewed Original ResearchMeSH KeywordsCost of IllnessDisabled PersonsFemaleGlobal Burden of DiseaseGlobal HealthHumansMaleQuality-Adjusted Life YearsRisk FactorsSurvivorsTuberculosisConceptsPost-tuberculosis sequelaeBurden estimatesTuberculosis diseaseDisease episodesIncident tuberculosisIncident tuberculosis casesIncident tuberculosis diseaseNon-fatal health lossOverall disease burdenPulmonary tuberculosis diseaseLifetime health outcomesDisease burden estimatesElevated mortality riskHigh incidence rateExtrapulmonary diseaseLung functionCase fatalityHIV statusLifetime burdenTuberculosis casesTotal DALYsDisease burdenIncidence rateHypothetical cohortTuberculosis survivorsThe Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease
Menzies NA, Shrestha S, Parriott A, Marks SM, Hill AN, Dowdy DW, Shete PB, Cohen T, Salomon JA. The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease. Epidemiology 2021, 33: 75-83. PMID: 34669631, PMCID: PMC8633045, DOI: 10.1097/ede.0000000000001418.Peer-Reviewed Original ResearchMeSH KeywordsHumansInterferon-gamma Release TestsLatent TuberculosisQuality-Adjusted Life YearsTuberculin TestTuberculosisUnited StatesConceptsPositive predictive valueHigh positive predictive valueFuture tuberculosisLatent tuberculosis infection treatmentIncremental costHigher treatment initiationCompletion of treatmentInterferon-gamma releaseQuality-adjusted life yearsTransmission dynamic modelLTBI testingTreatment initiationTreatment acceptanceTuberculosis diseasePrevention servicesPredictive valueTreatment servicesLife yearsTuberculosisInfection treatmentSocietal perspectiveIGRATreatment volumeHealth improvementFuture progression
2016
Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models
Menzies NA, Gomez GB, Bozzani F, Chatterjee S, Foster N, Baena IG, Laurence YV, Qiang S, Siroka A, Sweeney S, Verguet S, Arinaminpathy N, Azman AS, Bendavid E, Chang ST, Cohen T, Denholm JT, Dowdy DW, Eckhoff PA, Goldhaber-Fiebert JD, Handel A, Huynh GH, Lalli M, Lin HH, Mandal S, McBryde ES, Pandey S, Salomon JA, Suen SC, Sumner T, Trauer JM, Wagner BG, Whalen CC, Wu CY, Boccia D, Chadha VK, Charalambous S, Chin DP, Churchyard G, Daniels C, Dewan P, Ditiu L, Eaton JW, Grant AD, Hippner P, Hosseini M, Mametja D, Pretorius C, Pillay Y, Rade K, Sahu S, Wang L, Houben RMGJ, Kimerling ME, White RG, Vassall A. Cost-effectiveness and resource implications of aggressive action on tuberculosis in China, India, and South Africa: a combined analysis of nine models. The Lancet Global Health 2016, 4: e816-e826. PMID: 27720689, PMCID: PMC5527122, DOI: 10.1016/s2214-109x(16)30265-0.Peer-Reviewed Original ResearchMeSH KeywordsChinaCost-Benefit AnalysisDelivery of Health CareForecastingGoalsHealth Care CostsHealth ExpendituresHealth PolicyHealth ResourcesHealth Services AccessibilityHealth Services Needs and DemandHumansIndiaModels, TheoreticalPatient Acceptance of Health CareQuality-Adjusted Life YearsSouth AfricaTuberculosisConceptsPatient-incurred costsTuberculosis servicesConventional cost-effectiveness thresholdsHigh-burden countriesEnd TB StrategySubstantial health gainsNet cost savingsResource implicationsCost-effectiveness thresholdMost intervention approachesTB StrategyTuberculosis incidenceMost interventionsSocietal perspectiveHealth gainsIntervention mixMelinda Gates FoundationSubstantial healthHealth effectsCurrent practiceExpansion of accessIntervention approachesEmpirical cost dataCost dataIntervention
2013
Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. The Lancet Global Health 2013, 2: e23-34. PMID: 25104632, DOI: 10.1016/s2214-109x(13)70172-4.Peer-Reviewed Original ResearchConceptsHIV-positive adultsAdult antiretroviral therapyAntiretroviral therapyCD4 countTreatment coveragePotential health benefitsConcentrated epidemicsDALY avertedHealth benefitsEligibility criteriaExpansion of eligibilityEarlier eligibilityCD4 count thresholdHealth system perspectiveHead gross domestic productMiddle-income settingsGeneral populationHealth outcomesKey populationsTherapyHealth interventionsHealth budgetIncremental costMelinda Gates FoundationEligibility